Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (14766)	9/20/2000 12:10:17 AM
From: Bluegreen	Read Replies (3) \| Respond to of 17367

Bob, I would of approached this as Neuprex being STRICTLY an antibiotic synergist. NOT trying to reverse a G 8 or above sepsis event. IF YOU HAVE LEARNED ANYTHING FROM THIS LATEST TRIAL LEARN THIS............USE NEUPREX AS A PREVENTION OF FULL BLOWN SEPSIS NOT REVERSAL! USE IT TO RAPIDLY AND EFFECTIVELY KILL GRAM NEG BUGS BEFORE THE LOAD OF THIER LPS BROKEN UP MEMBRANES GET SO HIGH TO TRIGGER THE CASCADE!!! Take advantage also of BPI's ability to sop up LPS EARLY AND NOT SO MUCH TO TRIGGER CD14!!!!!! Just my opinions but the ONLY real definitive study with a mammal by direct gram neg bug infusion was the Baboon study. I take great comfort in commentary and Xoma agreeing that EARLY administration is important. ONE MORE TIME.....rapid AND effective killing EARLY on of gram neg bugs is VITAL!!! DO everything you can to prevent load buildup of LPS and kick off of CD14. Only way to prevent buildup is by preventing progeny appearance. If there is too much LPS to sop up even IF you have enough BPI you still will get vicious cycle of CD14 kickoff by the load. Once again only my opinions.

To: Robert K. who wrote (14766)	9/20/2000 3:12:13 AM
From: manfredhasler	Read Replies (1) \| Respond to of 17367

Robert, Re: I expect answer from each. Carefully. As has been done, i assume. I guess I had more insisted on a close monitoring by the steering committee (DSMB). With the option to terminate the study prematurely (due to not foreseen problems) or change the protocol in the course of the study (maybe more difficult on a prospective manner). As soon as it became evident that the first patients died due to logistic(?) problems the whole study design was to be questioned. Regards, Manfred